Company / Financials
ADMA Biologics, Inc. Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$510.2M
FY2025 · +19.6% YoY
Net Income
$146.9M
FY2025 · -25.7% YoY
Profit Margin
28.8%
FY2025 · net income / revenue
ROE
30.8%
FY2025 · return on equity
Total Assets
$624.2M
FY2025
Total Debt
$72.1M
0.15x debt/equity
Equity
$477.3M
FY2025
ROA
23.5%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$510.2M+19.6% YoYNet Income HistoryProfit after all expenses and taxes$146.9M-25.7% YoYGross Profit HistoryRevenue minus cost of goods sold$292.8M+33.3% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$217.4M+5.1% YoYOperating Income HistoryProfit from core business operations before interest and taxes$191.4M+37.7% YoYSG&A Expense HistorySelling, general, and administrative expenses$91.6M+23.5% YoYR&D Expense HistoryResearch and development spending$4.8M+162.7% YoYInterest Expense HistoryCost of borrowing and debt obligations$25.0MIncome Tax HistoryTotal income tax expense$35.7M+149.6% YoYEPS (Basic) HistoryBasic earnings per share-$0.13+60.6% YoY